[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616783":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":34,"responsibleParty":81,"collaborators":32,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":32,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":32,"enrollmentInfo":92,"targetDuration":32,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":32,"overallStatus":37,"whyStopped":32,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Xian-Janssen Pharmaceutical Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Guselkumab Treatment","EXPERIMENTAL","Participants will receive Guselkumab intravenously (IV) every 4 weeks during the induction phase, followed by subcutaneous (SC) administration of Guselkumab every 4 weeks from Week 12 through Week 44 as maintenance therapy.",[13],"Drug: Guselkumab (GUS)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Guselkumab (GUS)","Guselkumab will be administered intravenously or by subcutaneous injection.",[9],[21],"TREMFYA",[23],{"name":24,"affiliation":25,"role":26},"Xi'an Janssen Pharmaceutical Clinical Trial","Xi'an Janssen Pharmaceutical","STUDY_DIRECTOR",[28],{"name":29,"role":30,"phone":31,"phoneExt":32,"email":33},"Study Contact","CONTACT","844-434-4210",null,"Participate-In-This-Study1@its.jnj.com",[35,48,54,63,72],{"facility":36,"status":37,"city":38,"state":32,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":32},"The First Affiliated Hospital Sun Yat sen University","RECRUITING","Guangzhou","510060","China","CN",{"type":43,"coordinates":44},"Point",[45,46],113.25,23.11667,{"lat":46,"lon":45},{"facility":49,"status":37,"city":38,"state":32,"zip":50,"country":40,"countryCode":41,"cosmosGeoPoint":51,"geoPoint":53,"contacts":32},"The Sixth Affiliated Hospital Sun Yat sen University","510655",{"type":43,"coordinates":52},[45,46],{"lat":46,"lon":45},{"facility":55,"status":37,"city":56,"state":32,"zip":57,"country":40,"countryCode":41,"cosmosGeoPoint":58,"geoPoint":62,"contacts":32},"Sir Run Run Shaw Hospital Zhejiang University School of Medicine","Hangzhou","310018",{"type":43,"coordinates":59},[60,61],120.16142,30.29365,{"lat":61,"lon":60},{"facility":64,"status":37,"city":65,"state":32,"zip":66,"country":40,"countryCode":41,"cosmosGeoPoint":67,"geoPoint":71,"contacts":32},"The First Affiliated Hospital of Anhui Medical University","Hefei","230022",{"type":43,"coordinates":68},[69,70],117.28083,31.86389,{"lat":70,"lon":69},{"facility":73,"status":37,"city":74,"state":32,"zip":75,"country":40,"countryCode":41,"cosmosGeoPoint":76,"geoPoint":80,"contacts":32},"Ruijin Hospital","Shanghai","200031",{"type":43,"coordinates":77},[78,79],121.45806,31.22222,{"lat":79,"lon":78},{"type":82,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100616783","phase-4-a-study-to-evaluate-the-efficacy-of-guselkumab-in-chinese-participants-with-crohns-disease-cd-100616783",false,"NCT07310095","A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","Efficacy of Guselkumab in Chinese Participants With Crohn's Disease Following Loss of Response to Ustekinumab","Inclusion Criteria:\n\n* Has a confirmed diagnosis of Crohn's disease (CD)\n* Diagnosed with active CD, as defined by baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (\\>=) 220 and either mean daily stool frequency (SF) count \\>= 4 or mean daily abdominal pain (AP) score \\>=2\n* Participants had received at least two doses of ustekinumab (UST) (induction of 6 milligram \\[mg\\]\u002Fkilogram \\[kg\\] intravenous \\[IV\\] followed by 90 mg subcutaneous \\[SC\\] at week 8) as the instruction manual\n* Initially responded to UST induction therapy and then lose response to UST\n* During the screening period, participants are receiving UST treatment as the first line biologic or second line biologic\n\nExclusion Criteria:\n\n* Have responded well to treatment with UST in a dosing regime that is not in line with to the approved recommended dosing (for example, multiple intravenous induction) experienced optimized treatment with UST(not as instruction manual)\n* Participants with CD requiring urgent surgical or endoscopic intervention, or requiring elective surgery within 2 months\n* Is currently enrolled in an interventional clinical study\n* Complications of CD, such as symptomatic strictures or stenoses, short gut syndrome\n* Have a current or be suspected to have an abscess","ALL","18 Years",{"count":93,"type":94},78,"ESTIMATED","INTERVENTIONAL",[97],"PHASE4","The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.",[100],"Crohn Disease","2026-06-04",{"date":103,"type":104},"2026-06-05","ACTUAL",{"date":106,"type":104},"2025-12-30",{"date":108,"type":94},"2027-11-15",{"name":5,"class":6},5]